Lupin: Under pressure - Hold
The stock’s valuation is now attractive, but uncertainty in the US market is a concern
The Indian pharmaceutical industry has been going through a tough phase over the last couple of years. While the Nifty 50 index has gained over 15 per cent in absolute terms over the last two years, the Nifty pharma index has fallen nearly 33 per cent.Major pain points such as regulatory issues in the US market and pressure on drug pricing in the key markets have continued to weigh on the revenue ...
Read the rest of this article by Signing up for Portfolio.
It's completely free!
SIGN UP NOW
Investment alerts,End of day market reports, Market news analysis,External research reports and Technical calls
Daily update on Business and Market news via email
'Your Market Corner' Widget with personalized business and market news